Deutsch

enlarged text

COLLABORATION PARTNERS

Isotechnika Inc.
Based in Edmonton, Canada, Isotechnika Inc. focuses primarily on Research and Development of immune-modulatory medications. In May 2006 Lux Biosciences signed a license agreement with Isotechnika that gave access to LX211 (Isotechnika code ISA247) as well as the active ingredient exclusively and worldwide for ophthalmic indications. For further information please visit www.isotechnika.com

Rutgers, The State University of New Jersey, and the Center for Biomaterials
Established in 1766, Rutgers is America's eighth oldest institution of higher learning and one of the nation's premier public research universities. Serving more than 50,000 students on campuses in Camden, Newark and New Brunswick/Piscataway, Rutgers offers more than 280 bachelor's, master's, doctoral and professional degree programs. The university is home to 30 degree-granting schools and colleges, and more than 150 specialized centers and institutes. With 320,000 living alumni, Rutgers graduates are major contributors to all sectors of contemporary life.

The New Jersey Center for Biomaterials, directed by Professor Joachim Kohn,  is a research consortium of three universities (Rutgers, New Jersey Institute of Technology, and University of Medicine and Dentistry of New Jersey), about 20 corporate partners including large and small companies with interests in biomaterials science, and a diverse group of research-active faculty.  Established in 1997, the New Jersey Center for Biomaterials has grown into a major, federally funded research center with an extensive biomaterials patent portfolio. So far, six companies have licensed biomaterials technologies developed at the Center. 
For further information please visit www.njbiomaterials.org

University of Missouri - Kansas City
Lux Biosciences has established a research collaboration with the University of Missouri - Kansas City and with Professor Ashim Mitra, Chairman, Division of Pharmaceutical Sciences at the University of Missouri - Kansas City. Dr. Mitra is an internationally recognized expert in the field of ocular drug delivery and translational research in ophthalmology. For further information please visit http://pharmacy.umkc.edu/New/pharm/MITRA.html

The National Eye Institute (National Institutes of Health)
Lux Biosciences has collaborated with the National Eye Institute in the preclinical evaluation of its next generation calcineurin inhibitor. In addition, a CsA-eluting silicone matrix implant similar to LX201 has originally been developed by researchers at the NEI. This implant is being tested clinically at NEI in severe dry eye secondary to graft versus host disease. For further information please visit www.nei.nih.gov